List of Jesduvroq drug patents

Jesduvroq is owned by Glaxosmithkline.

Jesduvroq contains Daprodustat.

Jesduvroq has a total of 4 drug patents out of which 0 drug patents have expired.

Jesduvroq was authorised for market use on 01 February, 2023.

Jesduvroq is available in tablet;oral dosage forms.

Jesduvroq can be used as treatment of anemia due to chronic kidney disease, a method of treating anemia.

Drug patent challenges can be filed against Jesduvroq from 2027-02-01.

The generics of Jesduvroq are possible to be released after 13 March, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324208 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Dec, 2028

(5 years from now)

US11117871 GLAXOSMITHKLINE Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Mar, 2038

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815884 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(4 years from now)

US8557834 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 1, 2028

Drugs and Companies using DAPRODUSTAT ingredient

NCE-1 date: 2027-02-01

Market Authorisation Date: 01 February, 2023

Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia


More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in